+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Tigecycline Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • July 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5393433
Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously. Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over. These infections include complicated appendicitis, burn infection, intra-abdominal abscess, deep soft tissue infection and ulcer infection. Tigecycline was developed by Wyeth Corporation of the United States and was listed in China under the trade name TYGACIL in 2011. Subsequently, some generic drugs from local Chinese companies were listed. By 2020, tigecycline has been included in China's Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.





According to the market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

The analyst expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this. It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against "super bacteria" such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise. By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

Topics Covered:

  • The impact of COVID-19 on China's Tigecycline market
  • Sales value of China's Tigecycline 2016-2020
  • Competitive landscape of China's Tigecycline market
  • Prices of Tigecycline in China
  • Prices of Tigecycline in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Tigecycline market
  • Prospect of China's Tigecycline market from 2021 to 2025
Frequently Asked Questions about the Chinese Tigecycline Market

What is the estimated value of the Chinese Tigecycline Market?

The Chinese Tigecycline Market was estimated to be valued at CNY 323.45 Million in 2016.

What is the growth rate of the Chinese Tigecycline Market?

The growth rate of the Chinese Tigecycline Market is 23.7%, with an estimated value of CNY 2204.03 Million by 2025.

What is the forecasted size of the Chinese Tigecycline Market?

The Chinese Tigecycline Market is estimated to be worth CNY 2204.03 Million by 2025.

Who are the key companies in the Chinese Tigecycline Market?

Key companies in the Chinese Tigecycline Market include Pfizer Ltd (TYGACIL), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan), Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie) and Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia).

Table of Contents

1 Relevant Concepts of Tigecycline
1.1 Indications for Tigecycline
1.2 Development of Tigecycline in China
1.3 Governmental Approval of Tigecycline in China
1.4 The Impact of COVID-19 on Tigecycline sales in China

2 Sales of Tigecycline in China, 2016-2020
2.1 Sales Value of Tigecycline
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Tigecycline
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Tigecycline by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Tigecycline Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Tigecycline Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Pfizer Ltd
3.2.1 Enterprise Profile
3.2.2 Sales of TYGACIL (Pfizer Ltd’s Tigecycline) in China
3.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Zhetan (Jiangsu Hansoh Pharmaceutical Group Co., Ltd.’s Tigecycline) in China
3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Tianjie (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Tigecycline) in China
3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Hisun Liliang (Zhejiang Hisun Pharmaceutical Co., Ltd.’s Tigecycline) in China
3.6 Jiangsu Osaikang Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Aotijia (Jiangsu Osaikang Pharmaceutical Co., Ltd.’s Tigecycline) in China

4 Prices of Tigecycline for Different Manufacturers in China, 2020-2021
4.1 Pfizer Ltd (TYGACIL)
4.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)
4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)
4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)
4.5 Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia)

5 Prospect of Chinese Tigecycline drug Market, 2021-2025
5.1 Influential Factors of Chinese Tigecycline Market Development
5.1.1 The Impact of COVID-19 on Chinese Tigecycline Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Tigecycline Injection Registration in China
Chart Sales Value of Tigecycline Injection over the World
Chart Sales Value of Tigecycline Injection in China, 2016-2020
Chart Sales Value of Tigecycline Injection in China by Region, 2016-2020
Chart Sales Volume of Tigecycline Injection in China, 2016-2020
Chart Sales Volume of Tigecycline Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Tigecycline Manufacturers in China, 2016-2020
Chart Sales Value and Volume of TYGACIL in China, 2016-2020
Chart Sales Value and Volume of Zhetan in China, 2016-2020
Chart Sales Value and Volume of Tianjie in China, 2016-2020
Chart Sales Value and Volume of Hisun Liliang in China, 2016-2020
Chart Sales Value and Volume of Aotijia in China, 2016-2020
Chart Referential Prices of TYGACIL in China, 2020-2021
Chart Referential Prices of Zhetan in China, 2020-2021
Chart Referential Prices of Tianjie in China, 2020-2021
Chart Referential Prices of Hisun Liliang in China, 2020-2021
Chart Referential Prices of Aotijia in China, 2020-2021
Chart Forecast on Sales Value of Tigecycline in China, 2021-2025
Chart Forecast on Sales Volume of Tigecycline in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Ltd (TYGACIL)
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)
  • Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)
  • Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...